Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Megan Melch
Observed institution:
Alnylam Pharmaceuticals (United States)
OpenAlex ID:
A5004395437
Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects
2020
·
Bahru A. Habtemariam
, Verena Karsten
, et al.
·
Clinical Pharmacology & Therapeutics
·
186
Population Pharmacokinetic Analysis of the RNAi Therapeutic Givosiran in Patients with Acute Hepatic Porphyria
2023
·
Megan Melch
, Jongtae Lee
, et al.
·
Clinical Pharmacokinetics
·
7
Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation
2023
·
Prajakta Badri
, Bahru Habtemariam
, et al.
·
Clinical Pharmacokinetics
·
5
Pharmacokinetic‐pharmacodynamic model of urinary δ‐aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria
2023
·
Jongtae Lee
, Megan Melch
, et al.
·
CPT Pharmacometrics & Systems Pharmacology
·
4
PDF
Population Pharmacokinetic/Pharmacodynamic Analysis of Cemdisiran (ALN-CC5) in Healthy Subjects and Patients with Immunoglobulin A Nephropathy
2024
·
Wansu Park
, Megan Melch
, et al.
Disease Progression Modeling of Stargardt’s disease
2024
·
Satyawan B. Jadhav
, Nitin Mehrotra
, et al.
Show more works
View as search
Works count:
6
Citation count:
202
H-index:
4
I10-index:
1
Year
Topic
Type
